

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number [001-34058](#)

OMB APPROVAL

OMB Number:	3235-0080
Expires:	March 31, 2018
Estimated average burden hours per response:	1.7

Issuer: [Nile Therapeutics, Inc.](#)

Exchange: [NASDAQ Stock Market LLC](#)

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: [4 West 4th Avenue, Suite 400](#)
[San Mateo CALIFORNIA 94402](#)

Telephone number: [650-458-2670](#)

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

[Common Stock and Warrant](#)

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements for the Securities Exchange Act of 1934, [NASDAQ Stock Market LLC](#) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

[2011-07-13](#) By

[Amy Horton](#)

[Associate General Counsel](#)

Date

Name

Title

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. [See](#) General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC, July 13, 2011, Nile Therapeutics, Inc. The Nasdaq Stock Market, Inc. (the Exchange) has determined to remove from listing the common stock and warrant of Nile Therapeutics, Inc. (the Company), effective at the opening of the trading session on July 25, 2011. Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rule 5550(a)(2). The Company was notified of the Staffs determination on November 30, 2010. The Company appealed the determination to a Hearing Panel. Upon review of the information provided by the Company, the Panel issued a decision dated March 1, 2011, granting the Company continued listing pursuant to an exception through May 31, 2011, by which date the Company was required to regain compliance with Listing Rule 5550(a)(2). However, the Company did not regain compliance by that date. On May 10, 2011, the Panel issued a final delisting determination and notified the Company that trading in the Companys securities would be suspended on May 12, 2011. The Company did not request a review of the Panels decision by the Nasdaq Listing and Hearing Review Council. The Listing Council did not call the matter for review. The Panels Determination to delist the Company became final on June 24, 2011.